The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...
The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant ...
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
US FDA grants priority review to Sobi’s sBLA for Gamifant for use in adult and paediatric patients with HLH/MAS in Still’s disease: Stockholm Friday, February 28, 2025, 09:00 ...
17h
Hosted on MSNRegeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
The U.S. Food and Drug Administration (FDA) has accepted Sobi’s supplemental Biologics License Application (sBLA) for ...
USA News Group News Commentary ? Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being discussed among oncology experts around the world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results